HIMS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Hims & Hers Health, Inc. and Encourages Investors to Contact the Firm
If you purchased or acquired securities in Hims between April 29, 2025 and June 23, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
NEW YORK, Aug. 02, 2025 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. ('Hims & Hers' or the 'Company') (NYSE:HIMS) in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or otherwise acquired Hims securities between April 29, 2025 and June 23, 2025, both dates inclusive (the 'Class Period'). Investors have until August 25, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Click here to participate in the action.
The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, the Complaint alleges that Defendants failed to disclose to investors: (1) that Hims was engaged in the 'deceptive promotion and selling of illegitimate, knockoff versions of Wegovy® that put patient safety at risk;' (2) that, as a result, there was a substantial risk that the Company's collaboration with Novo Nordisk would be terminated; and (3) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Additionally, the Complaint alleges that Defendants made false and/or misleading statements, as well as failed to disclose material facts, including that: (1) the communication between Hims and the pharmaceutical company Novo Nordisk A/S ('Novo') would facilitate a long-term collaboration that would ensure continued access to the weight-loss drug Wegovy for Hims subscribers; (2) Novo approved of Hims' offerings of compounded semaglutide products under the 'personalization' exception; (3) branded Wegovy would be offered alongside compounded semaglutide options on the Hims platform, thereby expanding user choice; and (4) Defendants made positive statements abou the Novo partnership and Hims users' ongoing access to Wegovy alongside compounded semaglutide products.
If you purchased or otherwise acquired Hims & Hers shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at [email protected], telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com . Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.
Contact Information:
Bragar Eagel & Squire, P.C.Brandon Walker, Esq.Marion Passmore, Esq.(212) 355-4648
[email protected]
www.bespc.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
If You'd Invested $1,000 in JPMorgan Chase (JPM) 5 Years Ago, Here's How Much You'd Have Today
Key Points JPMorgan Chase has fared exceptionally well despite a changing macro landscape in the past few years. The stock's performance has been driven by soaring earnings. Investors might want to think twice before adding this business to their portfolios today. 10 stocks we like better than JPMorgan Chase › JPMorgan Chase (NYSE: JPM) continues to remind investors why it's the gold standard in the financial services industry. The largest U.S. bank reported revenue and earnings that crushed Wall Street estimates for the second quarter (ended June 30). Shares have been a big winner so far in 2025. The latest financial update is just another example of how JPMorgan Chase's business keeps humming along, to the benefit of long-term shareholders. If you invested $1,000 in this top bank stock five years ago, here's how much you'd have today. Navigating a dynamic macro environment For such a mature and massive entity, it can be surprising to learn that JPMorgan's stock has produced a total return of 253% in the past five years (as of July 31). This comes from a combination of the share price appreciating and the company's dividend payout, turning $1,000 into $3,530 today. What's impressive is that the business has successfully navigated a dynamic macro environment. Interest rates were extremely low after the onset of the COVID-19 pandemic, before rising rapidly in 2022. They appear to be on their way down, as the Federal Reserve is expected to cut rates before the year ends. Besides that, there have been supply chain bottlenecks, inflationary pressures, and the recent tariff uncertainty. In the face of these factors, JPMorgan's diluted earnings per share in Q2 2025 were still 280% higher than in the same period of 2020. Trading at a steep valuation This stock has been a huge winner in the past five years. Because of its current valuation, however, investors shouldn't expect a similar result between now and 2030. Shares trade at a price-to-book (P/B) ratio of over 2.4. That's a 92% premium compared to exactly five years ago. And it's essentially the stock's most expensive P/B multiple in two decades. JPMorgan Chase is a great business. But it's not a smart buy right now. Do the experts think JPMorgan Chase is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did JPMorgan Chase make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,019% vs. just 178% for the S&P — that is beating the market by 841.12%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 JPMorgan Chase is an advertising partner of Motley Fool Money. Neil Patel has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends JPMorgan Chase. The Motley Fool has a disclosure policy. If You'd Invested $1,000 in JPMorgan Chase (JPM) 5 Years Ago, Here's How Much You'd Have Today was originally published by The Motley Fool Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
8 minutes ago
- Yahoo
3 Great Energy Stocks to Buy This August
Key Points TotalEnergies is executing a unique long-term plan in the energy sector, using carbon profits to build a cleaner future. NextEra Energy sees powerful growth ahead. Brookfield Renewable is a top bet to play the renewable energy transition. 10 stocks we like better than NextEra Energy › Energy demand is growing briskly, and that bodes well for the companies producing the hydrocarbons we need today and those delivering the cleaner energy we'll need tomorrow. These energy companies should generate strong returns for investors as a result. TotalEnergies (NYSE: TTE), NextEra Energy (NYSE: NEE), and Brookfield Renewable (NYSE: BEPC) (NYSE: BEP) stand out to a few contributing analysts as great buys in the energy sector. Here's why they're such attractive investments this August. TotalEnergies is prepared for the clean energy transition Reuben Gregg Brewer (TotalEnergies): The integrated energy model that's being used by TotalEnergies stands out from its closest peers in a very important way. Most energy giants focus on owning assets that span from the upstream (production) through the midstream (pipelines) and on to the downstream (chemicals and refining). That's great, and it provides a way for investors to get energy exposure while softening the impact of volatile commodity prices. TotalEnergies adds electricity to the mix, with a collection of renewable power and electric generation assets. Although BP and Shell both professed to have similar ambitions in 2020, they have since walked back their plans on the electricity front. TotalEnergies, by contrast, has increased its focus on the space. And, notably, BP and Shell cut their dividends when they announced their clean energy shifts while TotalEnergies didn't cut, specifically stating that it recognized how important the dividend is to investors. So, in the end, BP and Shell investors were really just left with a dividend cut. TotalEnergies investors got dividend increases and the diversification benefit of the energy company's shift into electricity and clean energy. The really big benefit here, however, is long-term in nature. As peers focus on oil while the world slowly shifts toward renewable power, TotalEnergies is preparing today for the future. Add in a lofty 6.4% dividend yield (U.S. investors have to pay French taxes and fees on the income they collect), and Total Energies is a great long-term option in the energy patch. Powerful growth drivers Matt DiLallo (NextEra Energy): NextEra Energy is growing quickly, especially for a utility. Adjusted earnings per share rose 9.4% in the second quarter, powered by growth in its Florida electric utility and energy resources segment. The latter business continues to benefit from strong demand for renewable energy. NextEra's energy resource segment ended the first quarter with nearly 30 gigawatts of renewable projects in backlog, compared with 38 GW of operating assets. Building on this momentum, the company expects to keep growing in the coming years. NextEra projects its adjusted earnings per share will rise 6% to 8% annually through 2027. CEO John Ketchum said he would "be disappointed if we are not able to deliver financial results at or near the top of our adjusted earnings per share expectations ranges in each year through 2027, while maintaining our strong balance sheet and credit ratings." NextEra also expects about 10% annual dividend growth through at least next year. NextEra Energy should keep growing at a healthy rate well beyond that. Analysts expect U.S. power demand to surge in the coming decades, driven by the growth of AI data centers, electrification, and the onshoring of manufacturing. This will require far more renewable energy capacity. As a renewable-energy leader, NextEra Energy should benefit from this sector's surging demand. Given these strong growth prospects and its attractive dividend yield of more than 3%, NextEra stands out as a compelling long-term investment. With its share price having dropped nearly 10% since the company reported second-quarter earnings last month, it's a great buy this August. A top-notch energy dividend stock Neha Chamaria (Brookfield Renewable): The Trump administration's shift away from renewables won't stop the global energy transition. Global renewable electricity generation is projected to grow by nearly 90% between 2023 and 2030, according to the International Energy Agency. The BloombergNEF's new energy outlook 2025, meanwhile, projects renewable generation to grow by 84% between 2025 and 2030, and then double by 2050. Buying a top-notch renewable energy stock like Brookfield Renewable could therefore be one of your smartest investing moves now. That's because Brookfield Renewable not only generates over 40% cash flows from markets outside North America but is also one of the most diversified renewable energy plays, with operations across hydropower, wind, solar, and distributed energy and storage. Brookfield Renewable just signed a first-of-its-kind hydro power agreement with tech giant Google to deliver up to 3,000 megawatts of hydroelectric power in the U.S. This deal comes on the back of yet another solid quarter, with Brookfield Renewable generating record funds from operations (FFO) in its second quarter, up 10% year over year. With an ever-growing pipeline and a projected boom in demand for electricity driven by data centers, Brookfield Renewable is in the sweet spot and expects to grow its annual FFO per unit by over 10% in the long term. With Brookfield Renewable also targeting 5% to 9% annual dividend growth and its corporate shares yielding 4%, this energy stock is also among the top 10 dividend stocks to double up on now. Do the experts think NextEra Energy is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did NextEra Energy make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,019% vs. just 178% for the S&P — that is beating the market by 841.12%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Matt DiLallo has positions in Brookfield Renewable, Brookfield Renewable Partners, and NextEra Energy. Neha Chamaria has no position in any of the stocks mentioned. Reuben Gregg Brewer has positions in Brookfield Renewable Partners and TotalEnergies. The Motley Fool has positions in and recommends NextEra Energy. The Motley Fool recommends BP, Brookfield Renewable, and Brookfield Renewable Partners. The Motley Fool has a disclosure policy. 3 Great Energy Stocks to Buy This August was originally published by The Motley Fool
Axios
9 minutes ago
- Axios
More pharma giants embrace direct-to-consumer sales
Drugmakers are increasingly using telehealth platforms to sell their medicines directly to patients — and President Trump is pushing for more companies to get into the game. Why it matters: Direct-to-consumer sales require only a few mouse clicks, often without the need to manage appointments or insurance forms. Online sales can also bypass pharmacy middlemen, in theory lowering prices and providing more transparency into what patients have to pay. But there are tradeoffs, like the prospect of overprescribing or manufacturers steering patients toward expensive name-brand drugs. Driving the news: Trump on Thursday sent letters to the CEOs of 17 pharmaceutical companies, demanding they bring down U.S. prices within 60 days. The requirements include providing direct-to-consumer or direct-to-business drug purchasing models for certain products. Several pharma giants have already committed to these models or are exploring them, in part driven by the surging popularity of GLP-1 drugs that are expensive and often not covered by insurance. Eli Lilly last year became the first pharmaceutical company to launch a direct-to-consumer health care platform for its diabetes, obesity, migraine and select other medications. Pfizer and Novo Nordisk have since launched their own direct sales models, and the CEO of Roche said last month that the company is considering something similar for U.S. patients. In the first quarter of this year, about 25% of new prescriptions for Lilly's weight-loss drug Zepbound were fulfilled through LillyDirect, per a spokesperson. Consumer health companies like Hims & Hers have also helped popularize the concept among patients. How it works: Lilly's and Pfizer's DTC models start with virtual visits with independent practitioners working with telehealth platforms, who can — but are not obligated to — prescribe medicines in each company's program. Patients can then order medications directly from the company, and can often arrange to have them delivered to their homes. Some drugs on Lilly's DTC platform, including vials of Zepbound, are only available for patients who pay cash, which streamlines the process. Patients can use their commercial insurance for other drugs. Novo Nordisk's platform doesn't include the telehealth appointment but allows cash-paying patients who take GLP-1 drug Wegovy to have their prescription sent directly to the company. Patients can qualify for a lower price for the drug and home delivery. The other side: Direct-to-consumer models run the risk of pushing drugs on patients who may not need them, Adam Brown, a physician and health care strategist, wrote in a September op-ed in MedPage Today. Pharmacy benefit managers, who serve as intermediaries between health plans and the manufacturers, also want to temper enthusiasm for the new systems and claim they can save more. "PBMs want lower prices on every drug for every patient, and direct to consumer channels may provide one more way for some patients to gain access to some medications," Greg Lopes, vice president of public affairs and communications for the Pharmaceutical Care Management Association, said in an email. "In most cases however, patients will spend less out of pocket and face fewer safety concerns when their medications are delivered through their prescription drug benefits at their pharmacies and with their doctors involved." The intrigue: While Trump is pushing direct-to-consumer drug sales, Health Secretary Robert F. Kennedy Jr. has long been interested in limiting pharmaceutical companies' ability to advertise to consumers. Health and Human Services is "exploring ways to restore more rigorous oversight and improve the quality of information presented to American consumers who deserve nothing less than radical transparency," spokesperson Emily Hilliard told Axios.
